KMT2A and breast carcinoma: For example, transfection with Trx1 increases NIH 3T3 cell proliferation and stimulates tumor formation of MCF-7 breast cancer cells, whereas transfection with dominant-negative mutant Trx1 (C32S/C35S) delays tumor progression and metastasis [6].